All currently marketed oral PPIs in the U

PPIs are widely prescribed for a variety of diseases and disorders of the upperdigestive tract. All currently marketed oral PPIs in the U.S., other thanZEGERID, are delayed-release formulations that utilize an enteric coating toprotect the PPI from acid degradation, thereby delaying absorption and initialacid suppression. Unlike delayed-release PPIs, ZEGERID Capsules and Powder forOral Suspension utilize an antacid in lieu of an enteric coating. The antacidneutralizes stomach acid and protects the PPI, omeprazole, from gastric aciddegradation and allows for its rapid absorption and suppression of gastric acid.Important Safety Information About ZEGERID Capsules and Powder for OralSuspensionThe most frequently reported adverse events with ZEGERID are headache, diarrhea,and abdominal pain. In 178 critically ill patients treated with ZEGERID Powderfor Oral Suspension, adverse events generally reflected the serious, underlyingmedical condition of the patients, but some adverse events occurred with morefrequency in patients treated with ZEGERID Powder for Oral Suspension than inthose treated with the comparator (acid-controlling) drug. Atrophic gastritis has been notedoccasionally in gastric corpus biopsies from patients treated long term withomeprazole ZEGERID Capsules contain 304 mg of sodium per dose.

ZEGERID Powder for OralSuspension contains 460 mg of sodium per dose. Sodium bicarbonate is contraindicated in patients with metabolic alkalosis andhypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivityto any component of the formulation. Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate(1100 mg in capsules, 1680 mg in packets of powder for oral suspension), two 20mg capsules are not equivalent to, and should not be substituted for, one 40 mgcapsule, and two 20 mg packets are not equivalent to, and should not besubstituted for, one 40 mg packet About SantarusSantarus, Inc.

The companys current commercial efforts are primarily focused onZEGERID (omeprazole/sodium bicarbonate) Capsules and Powder for OralSuspension, which are indicated for the treatment of certain upper GI diseasesand disorders, and on GLUMETZA (metformin hydrochloride extended releasetablets), which are indicated as an adjunct to diet and exercise to improveglycemic control in adults with type 2 diabetes. Santarus is also developing twolate-stage lower GI compounds, budesonide MMX and rifamycin SV MMX for theU.S market. Budesonide MMX is being investigated in two multi-center Phase IIIclinical trials for the induction of remission of mild-to-moderate ulcerativecolitis. Rifamycin SV MMX has been investigated in a Phase II clinical programin travelers diarrhea. More information about Santarus is available on thecompanys Web site at Santarus cautions you that statements included in this press release that arenot a description of historical facts are forward-looking statements. Theinclusion of forward-looking statements should not be regarded as arepresentation by Santarus that any of its plans or objectives will be achieved.Actual results may differ materially from those set forth in this release due tothe risks and uncertainties inherent in Santarus business, including, withoutlimitation:whether the FDA accepts the NDA for the new tablet product for filingor ultimately approves the NDA in a timely matter or at all; the timing forcommercial availability of the new tablet product and potential for delaysassociated with the regulatory approval process; whether, subject to receipt ofFDA approval, Santarus is able to generate market demand and acceptance for thenew tablet product; the scope and validity of patent protection for the newtablet product and Santarus other ZEGERID products, including the outcome andduration of the pending patent infringement lawsuits against Par Pharmaceutical,Inc., and Santarus ability to commercialize the new tablet product and itsother ZEGERID products without infringing the patent rights of others; otherdifficulties or delays in development, testing, manufacturing and marketing of,and maintaining regulatory approvals for, Santarus products; and other risksdetailed in Santarus prior press releases as well as in public periodic filingswith the Securities and Exchange Commission.You are cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof.All forward-lookingstatements are qualified in their entirety by this cautionary statement andSantarus undertakes no obligation to revise or update this news release toreflect events or circumstances after the date hereof.This caution is made underthe safe harbor provisions of Section 21E of the Private Securities LitigationReform Act of 1995.Santarus and ZEGERID are registered trademarks of Santarus, Inc.

GLUMETZA isa trademark of Biovail Laboratories International S.r.l. licensed exclusively inthe United States to Depomed, Inc.MMX is a registered trademark of CosmoTechnologies Ltd.Company Contact:Martha L Hough, VP Finance & Investor Relations, 858-314-5824Debra P. Crawford, Chief Financial Officer, 858-314-5708orInvestor Contact:Lippert/Heilshorn & Associates, Inc.Jody Cain or Kevin Mc Cabe, Copyright Business Wire 2009. DUBLIN, Ireland(Business Wire)Research andMarkets( http://)has announced the addition of the "Chinese Markets for Biopharmaceuticals"report to their offering. In the next five years, both production and demand will continue togrow. This new study examines China's economic trends, investment environment,industry development, supply and demand, industry capacity, industry structure,marketing channels and major industry participants. Historical data (1998, 2003and 2008) and long-term forecasts through to 2013 and 2018 are presented Majorproducers in China are profiled.